The multidrug resistance (MDR) phenotype, induced by the overexpression of several ABC transporters or by antiapoptotic mechanisms, has been identified as the major cause of drug resistance in the treatment of patients with acute myeloid leukemia (AML). In this study, we have shown that valproic acid (VPA) (a histone deacetylase inhibitor) can inhibit the proliferation of both P-glycoprotein (P-gp)-and MDR-associated protein 1 (MRP1)-positive and -negative cells. VPA also induced apoptosis of P-gp-positive cells. VPA induced apoptosis in K562 cells led to decrease in Flip (FLICE/caspase-8 inhibitory protein) expression with Flip cleavage, which could not be observed in HL60 cells. In HL60/MRP cell line, which proved to be resistant to apoptosis by VPA, we observed an abnormal expression of apoptotic regulatory proteins, overexpression of Bcl-2 and absence of Bax. Also, the Bcl-2 antagonist HA14-1 rapidly restored apoptosis in this cell line. Cotreatment with cytosine arabinoside induced very strong apoptosis in both K562/DOX and HL60/DNR cell lines. VPA also induced apoptosis in AML patient cells expressing P-gp and/or MRP1. Our findings show VPA as an interesting drug that should be tested in clinical trials for overcoming the MDR phenotype in AML patients.
Introduction
Drug resistance remains a major problem in the treatment of patients with acute myeloid leukemia (AML). The ABC (ATPbinding cassette) transporters P-glycoprotein (P-gp) and multidrug resistance protein (MRP1), which act as an ATP-dependent xenobiotic membrane efflux pump, 1, 2 have been identified as a poor prognostic factor in AML patients treated with anthracyclines and cytosine arabinoside (Ara-C). 3, 4 In this setting, the efficacy of histone deacetylase (HDAC) inhibitors, a novel class of chemotherapeutic agents, has to be explored. Histone acetylation plays a key role in the regulation of transcription by modulation of chromatin structure. HDAC inhibitors had been shown to induce cell differentiation, inhibit cell cycle and induce apoptosis in a wide range of tumourderived cell lines in vitro. They also block angiogenesis and stimulate immune system in vivo. 5, 6 HDAC inhibitors have a selective toxicity against tumor cells and a synergistic activity with existing therapeutic agents, including retinoic acids, 7 vitamin D analogues 8 and peroxisome proliferator-activated receptor ligands. 9 A number of HDAC inhibitors are currently in phase I and II clinical trials (eg depsipeptide, AN-9: pivaloyloxymethyl butyrate), and encouraging results have been reported for their use in the treatment of both hematological malignancies and solid tumors. 5, 6 Phase I clinical trial showed suberoylanilide hydroxamic acid (an HDAC inhibitor) to have an antitumor activity in both solid and hematological tumors and to be well tolerated. 10 Valproic acid (VPA) is a drug currently used in the treatment of epilepsy. VPA is well tolerated by patients and has been shown to have a marked HDAC inhibitor effect at the pharmaceutical level, inducing differentiation and apoptosis of transformed cells. 11, 12 In this paper, we show that VPA is not a substrate of P-gp and MRP1, and that it does not modify their expression. We also show that VPA can induce cell cycle arrest and apoptosis in both Pgp-positive and -negative leukemia cells from cell lines and AML samples. Our findings show that VPA is an interesting drug to be tested in clinical trials for overcoming the MDR phenotype in leukemia.
Material and methods

Cell cultures
The studies were carried out with human bcr-abl myeloid leukemia cells (K562S), human promyelocytic leukemia cells (HL60S) and their P-gp-or MRP1-expressing derivations: K562/ DOX, HHT300, HL60/DNR and HL60/MRP cell lines. The cells were cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS), penicillin 50 U/ml and streptomycin 50 mg/ml and incubated in a humidified atmosphere containing 5% CO 2 . Valproic acid (Sigma, France) was used at concentration of 4 mM. Bcl-2 inhibitor, HA14-1, was purchased from Biomol (Plymouth Meeting, PA, USA).
Patients
Peripheral blood samples from 13 AML patients were obtained after their informed consent. Mononuclear cells were isolated using Ficoll-Hypaque density gradient. The percentage of blasts was 480%. The fresh leukemia cells were cultured in the same general conditions as the cell lines, but treated with VPA 1 mM, the pharmacological concentration of VPA.
Apoptosis assay
A total of 10 6 cells were stained with both propidium iodide (PI) (5 mg/ml) and 15 ml/ml Annexin-V/FITC in calcium-HEPES buffer for 15 min as recommended by the manufacturer (Roche, France). The percentage of apoptotic cells was determined by flow cytometry.
Cell proliferation and cell cycle analysis
Cell proliferation was quantified by cell counting using trypan blue. Cell cycle analysis was performed after BrdU exposure. 13 
Western blot analysis
Whole-cell extracts were prepared by lysing with RIPA buffer. Total protein (50 mg) was put on 7.5 or 12% SDS-PAGE gel for separation.
14 Cyclin D3, cyclin A, cyclin E, Bax, Flip (FLICE/ caspase-8 inhibitory protein) and p27kip1 antibodies were purchased from Santa Cruz Biotechnology (CA, USA); PARP, Bcl-2, phospho-stat5 and p21 antibodies from Pharmingen (San Diego, USA); acetyl-histone H4 and anti-acetyl-lysine from Upstate biotechnology (Lake Placid, USA).
Mitochondrial membrane potential
Changes in the inner mitochondrial transmembrane potential were determined by incubation of 10 6 cells in phosphatebuffered saline (PBS) for 15 min at 371C in the presence of 40 nM DiOC 6 (3) (Molecular Probes, USA). The cells were washed once in PBS and then suspended in PBS with PI. The flow cytometry histograms were recorded.
P-gp and MRP1 expression analysis
A total of 10 6 cells were incubated with UIC2 (Immunotech, France) or QCRL3 (Alexis, CA, USA) monoclonal antibodies, and then labeled with a secondary antibody conjugated with phycoerythrin. The fluorescence was measured and analyzed on Epics ALTRA flow cytometer (Beckman Coulter, USA) and compared to the controls using the Kolmogorov-Smirnov test. P-gp/MRP1 expression was considered as positive if D40.20.
Results
VPA inhibits cell growth in sensitive K562S, HL60S cell lines, but also the P-gp-or MRP1-expressing K562/ DOX, HHT300, HL60/DNR, HL60/MRP cell lines First, we have compared the cell growth of MDR-negative (K562S, HL60S) and P-gp-(K562/DOX, HHT300 and HL60/ DNR) or MRP1-(HL60/MRP) expressing cell lines in the presence of 4 mM VPA. All the cell lines were harvested initially at the concentration of 0.2 million/ml, and the cells were counted every day by trypan blue. We observed complete inhibition of cell growth by VPA in all cell lines including those expressing a functional P-gp or MRP1 protein and therefore resistant to daunorubicin, doxorubin or homoharringtonin ( Figure 1 ). Cell growth inhibition by VPA was equivalent in sensitive MDR and MRP1 cell lines.
VPA induces cell growth arrest in G1 phase
We analyzed the cell cycle by BrdU incorporation and PI staining after the treatment of K562S, K562/DOX, HHT300, HL60S, HL60/DNR and HL60/MRP cells with VPA for 24, 48 and 72 h. Our analysis revealed a block in G1 phase and a reduced number of cells in S phase after 48 h of treatment with VPA ( Table 1 ). The beginning of the changes was observed at 24 h, while we failed to evaluate the cell cycle at 72 h due to massive apoptosis. The minimal difference of phase S cell percentage between nontreated and treated cells was 20%. This phenomenon was accompanied by the concomitant increase in the expression of cyclin E and cyclin D3, and decrease in expression of cyclin A, an S phase cyclin (Figure 2a ), confirming the G1 phase block by VPA in all cell lines.
VPA induced the accumulation of p27, the main inhibitor of the cyclin-cdk complex, in all of the cell lines. On the other hand, the expression of p21, another cyclin-cdk inhibitor, was induced only in HL60 cell lines, but not in K562 cell lines ( Figure 2b ). VPA inhibits cell growth in K562, HL60 and their derivation cells. K562S, K562/DOX, HHT300, HL60S, HL60/DNR and HL60/MRP cells were treated by 4 mM VPA for 3 days and counted by trypan blue every day. Each cell line was tested at least three times. Cell cycle profile and distribution of untreated controls and treated cells by 4 mM VPA at day 2 were determined by BrdU incorporation and PI staining. The percentage of cells in sub-G1 region indicates VPA-induced cell death.
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VPA induces apoptosis in P-gp-expressing K562 and HL60 cells, but not in HL60/MRP cells expressing MRP1
At day 3, the nontreated and VPA 4 mM treated cells were stained by Annexin-V, and the percentage of apoptotic cells determined by flow cytometry. K562/DOX, HHT300 and HL60/ DNR P-gp-expressing cells showed to be more sensitive to VPA than the K562S P-gp-nonexpressing cells (Figure 3a) . In contrast, VPA could not induce cell death in HL60/MRP cells, although it did inhibit cell growth in these cells as well. Subsequently, we assessed the functional role of caspases in VPA-induced apoptosis after 48 h of treatment. The cleavage of PARP, cleaved by caspases during apoptosis, was analyzed by Western immunoblotting (Figure 3b ). VPA induced a strong 85 kDa PARP cleavage fragment in K562/DOX and HHT300 cell lines, but only a small one in HL60S and HL60/DNR cells. The explanation for this could be that apoptosis induced by VPA in K562 and its derivation cells is caspase dependent, while this may not be the case with HL60 and its derivation cells.
VPA inhibits HDAC activity in K562 and HL60 cells expressing P-gp or MRP1, without a change in the expression and activity of P-gp and MRP1
Inhibition of HDAC activity results in histone acetylation. The in vitro histone acetylation test was performed using a specific antibody for acetyl-lysine and a specific antibody for acetylhistone H4. We observed a strong histone H4 acetylation in K562/DOX, HHT300, HL60/DNR and HL60/MRP cells in the presence of 4 mM VPA (Figure 4 ). At day 2, the acetylation reached maximum and started to decrease from day 3.
Histone acetylation results in increased recruitment of DNAbinding transcription factors, which in turn leads to the increase or decrease of expression of the downstream genes. Using specific antibodies against P-gp and MRP1, we did not find a change in the expression of P-gp and MRP1 in the cells treated with VPA. Using specific modulators for P-gp and MRP1, cyclosporine and MK571, respectively, we assayed the activity of P-gp and MRP1, and VPA did not alter either P-gp or MRP1 activity, in any of the cells studied (data not shown). Expression of cell cycle proteins. The cells were treated with 4 mM VPA for 48 h. The protein expressions were analyzed by Western blot using cyclin A, cyclin E, cyclin D3, p27 kip1 and p21-specific antibodies (CON ¼ control). Figure 5 ). However, there was no decrease of Flip expression in HL60/ DNR cells ( Figure 5) ; the expression of Flip may have even increased slightly, which may explain the moderate PARP cleavage in HL60/DNR cells. The same, the Flip cleavage, was also observed in K562S cells ( Figure 5 ), but not in HL60S and HL60/MRP cells (data not shown). Therefore, we propose a different mechanism of cell death involved in the induction of programmed cell death by VPA in HL60 compared to K562 cell lines.
VPA induces a decrease in
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Reduction of tyrosine phosphorylated Stat5 in K562S and K562/DOX cells
We also looked into the tyrosine-phosphorylated Stat5 protein; since it has been shown that Stat5 activation contributes to growth and viability in Bcr/Abl-transformed cells. 15 Using a specific antiphosphorylated Stat5 antibody, we observed a reduction of phosphorylated Stat5 protein in K562S and K562/ DOX cells, but not in HL60/DNR cells ( Figure 5 ).
Bcl-2 overexpression and absence of Bax in HL60/MRP cells ground for lack of apoptosis in response to VPA
To determine whether the MRP1 protein was responsible for the lack of apoptosis in the MRP1-expressing HL60/MRP cells treated with VPA, we treated these cells with VPA and MRP1 modulators (probenecid and MK571) to block the efflux pump. The percentage of apoptotic cells did not increase. Subsequently, we were interested to see the involvement of the Bcl-2 family protein members in our cell lines. We found an overexpression of Bcl-2 and an absence of Bax in HL60/MRP cells (Figure 6a ), while there was only a modest change in the ratio of expression of Bcl-2 and Bax in other cell lines treated with VPA.
To see whether the lack of apoptosis in HL60/MRP cells was indeed due to Bcl-2 expression, we treated the cells with the Bcl-2 antagonist HA14-1. After only 24 h of incubation with 10 À5 M HA14-1, at time preceding the full action of VPA (72 h), we observed a very strong apoptotic response. This was also accompanied by the cleavage of Bcl-2 on Western blot (Figure 6b ). The action of HA14-1 being prompter than that of VPA, we could not demonstrate the restoration of apoptosis by HA14-1 in HL60/MRP cells treated with VPA. It would be interesting to explore the action of apoptotic regulatory proteins, especially the role of Bcl-2 and Bax, in this cell line.
VPA does not induce disruption of the mitochondria in K562/DOX and HL60/DNR cells K562/DOX and HL60/DNR cells treated with VPA and the controls were labeled with DiOC 6 (3) and PI on day 3. We observed an increase of the staining with PI in K562/DOX and HL60/DNR cells treated with 4 mM VPA, indicating that the cells were committed to death. This was also confirmed on the staining with Annexin-V/FITC (data not shown). However, there was no change in the fluorescence intensity on the staining with DiOC 6 (3) compared to controls: the fluorescence intensity remained high, suggesting that the mitochondria were not involved (supplementary Figure 1: at website). Apoptosis accompanied by a decrease of the DiOC 6 fluorescence intensity, indicating mitochondria disruption, was observed only in the HL60/MRP cells, shown to overexpress Bcl-2, with the usage of the Bcl-2 antagonist HA14-1 (supplementary Figure  1: at website).
Combined treatment with VPA and Ara-C induces very strong apoptosis in K562/DOX and HL60/DNR cells
We investigated the combined treatment with VPA and Ara-C, a nucleoside analogue (P-gp and MRP1 independent), conventionally used for the treatment of AML patients. Until day 3, treatment with Ara-C in the concentration of 10 À6 M provoked the death of 66% and treatment with VPA 4 mM 49% of K562/ DOX cells, and 70% (Ara-C 10 À5 M) and 34% (VPA 4 mM) of HL60/DNR cells. When the cells were cotreated with both Ara-C (10 À6 M) and VPA (4 mM), the two drugs together provoked the death of 90% of K562/DOX cells and 94% of HL60/DNR cells (Ara-C, 10 À5 M) (supplementary Figure 2: at website). 
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VPA induces apoptosis in AML patient cells expressing P-gp and MRP1
Subsequently, we wanted to see the effect of VPA on apoptosis of fresh leukemia cells of AML patients in relation to the expression of P-gp and MRP1 on fresh leukemia cells when treated with VPA in the pharmacological concentration of 1 mM. We observed strong apoptosis induced by 1 mM VPA independent of P-gp and MRP1 expression ( Table 2 ). VPA inhibited HDAC activity and resulted in histone acetylation in the P-gpand MRP1-expressing patient cells (data not shown).
Discussion
Numerous studies demonstrate that HDAC inhibitors, a novel and promising class of chemotherapeutic agents, which can inhibit cell cycle progression, also induce apoptosis and differentiation. 5, 6 However, little is known about HDAC inhibitors and MDR-expressing cancer cells, especially about VPA and P-gp and/or MRP1 resistance. Several authors showed recently that cotreatment with the HDAC inhibitor SAHA promoted STI571-mediated apoptosis in both STI571-sensitive and -resistant Bcr/ABL þ human myeloid leukemia cells. 16, 17 At the same time, Peart et al 18 demonstrated that SAHA and oxamflatin, but not depsipeptide (all HDAC inhibitors), could kill P-gp þ cells. The results of our study show that VPA inhibits the proliferation of P-gp-and MRP1-expressing K562/DOX, HHT300, HL60/DNR and HL60/MRP cells as well as P-gp-and MRP1-nonexpressing K562S and HL60S cells. VPA also induced apoptosis in all of these P-gp-expressing cells. The sensitivity to VPA proved to be independent of P-gp and MRP1 expression in these cells. These effects of VPA were concomitant with the VPA inhibition of HDAC activity, resulting in histone H4 acetylation in these P-gp-and MRP1-expressing cells. The apoptosis induced by the cotreatment with VPA and Ara-C reached more then 90% at day 3. All our findings so far suggest a possible new clinical option for the patients who relapsed after the treatment with anthracycline and Ara-C.
VPA and other HDAC inhibitors were shown to induce differentiation of leukemia blasts and trigger the terminal differentiation in AML cells when cotreated with retinoic acid. 19 We also wanted to find out whether the cells that underwent apoptosis induced by VPA at day 3 differentiated. We did not observe the appearance of nitroblue tetrazolium-positive cells and the increased CD11b expression at day 3. It seems that there was no myeloid differentiation of cells until the time when the cells went to apoptosis.
We were particularly interested in molecular mechanisms involving (a) inhibition of cell proliferation and (b) induction of apoptosis in P-gp-and MRP1-positive cells. Inhibition of cell proliferation by different HDAC inhibitors in different cell lines corresponds to either G1 or G2/M cell cycle arrest of these cells. 20, 21 In our study, we show that VPA induced cell growth arrest in G1 phase and upregulation of the expression of p27 kip1 . The expression of p21 was induced in HL60 cells, but not in K562 cells. The G1 cell cycle arrest independent of p21 induction has been documented in SAHA-induced apoptosis of K562 and U937 cells. 17, 21 Somewhat increased expression of cyclin D3 and a highly increased expression of cyclin E propose a late G1 arrest in all cells except the HL60/MRP cells. A late G1 arrest and the upregulation of the expression of p27 kip1 may be necessary for VPA-induced apoptosis.
A number of studies have demonstrated that overexpression of Bcl-2 protects cells against diverse apoptotic agents. 22 Bcl-2 overexpression inhibits mitochondrial membrane damage and apoptosis induced by HDAC inhibitors. We observed a lack of apoptosis in HL60/MRP cells treated with VPA, with an overexpression of Bcl-2 and an absence of expression of Bax. In these cells, the Bcl-2 antagonist HA14-1 provoked strong apoptosis at day 1, acting much earlier than VPA, which develops its full activity by day 3. The prompt action of HA14-1 did not permit us to demonstrate direct involvement of Bcl-2 in resistance to apoptosis induced by VPA; still, our results do suggest that the Bcl-2 overexpression plays an important role in the inhibition of apoptosis in HL60/MRP cells, also in response to VPA.
A number of studies have shown that apoptosis induced by HDAC inhibitors alone or combined with other agents involved mitochondrial membrane damage. 17, 23, 24 The mitochondrial membrane damage was accompanied by cytochrome c release, or decline of the mcl-1/Bcl-xL expression, or Bid cleavage. The apoptosis induced by HDAC inhibitors alone or combined with other agents also involved the inactivation of the signal transduction pathways, viewed as a decline in expressions of phospho-Mek1/2, phospho-erk1/2 and phospho-Akt. 25 In our study, we found a decreased phospho-Stat5 expression in K562 cells. However, we have examined the ratio of Bcl-2/Bax expression and we did not observe a decline in the expression of Bcl-2 and Bax in any cell lines. Using DiOC 6 (3) as the marker of Expression of P-gp and MRP1 from fresh patients cells was determined by flow cytometry using their respective specific antibodies. The percentage of apoptotic cells after 48 h of treatment with 1 mM VPA (pharmacological concentration) determined by flow cytometry using Annexin-V staining.
Valproic acid in Pgp þ and MRP1 þ cells R Tang et al mitochondrial involvement, we did not observe the involvement of the mitochondria in the apoptosis of the K562/DOX and HL60/DNR cells induced by VPA. On the opposite, the mitochondria were involved in the apoptosis of the HL60/MRP cells, shown to overexpress Bcl-2, induced after the usage of the Bcl-2 antagonist HA14-1.
Depsipeptide induces activation of caspase-8-mediated apoptosis and downregulation of Flip protein. 26 In AML cells, synthetic triterpenoids activate a pathway for apoptosis involving downregulation of Flip and sensitization to TRAIL. 27 We found a downregulation of Flip with a cleavage 38 kDa Flip in K562 cells, but not in HL60 cells. We propose a different mechanism of apoptosis induced by VPA. It may be that VPA sensibilizes the death domain apoptosis pathway (apoptosis pathway activated by death receptors of the TNF family). Next, it would be interesting to see if a synergic effect could be obtained combining VPA with signaling through a death receptors of the TNF family.
So far, we were able to study the effect of VPA in cells of only a few AML patients. Still, we were able to show that VPA in the pharmacological concentration of 1 mM could induce apoptosis also of the P-gp-and/or MRP1-positive cells of AML patients. The results encourage us to see whether the results obtained so far are consistent in AML patients, and whether VPA has the same effect on the cells of AML patients treated with Ara-C, the standard treatment in AML, and to establish if VPA could be used as help for overcoming of the MDR phenotype in AML leukemia.
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